Results 11 to 20 of about 2,229,234 (312)

Acute lymphoblastic leukemia [PDF]

open access: yesPediatric Blood & Cancer, 2021
Abstract The survival of patients with acute lymphoblastic leukemia (ALL) has improved significantly with the use of intensive multimodality treatment regimens including chemotherapy, high‐dose chemotherapy and stem cell rescue, and radiation therapy when indicated. This report summarizes the treatment strategies, especially radiation
John Han‐Chih Chang   +4 more
openaire   +2 more sources

Acute Lymphoblastic Leukemia [PDF]

open access: yesJournal of the National Comprehensive Cancer Network, 2012
The inaugural NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) were developed as a result of meetings convened by a multi-disciplinary panel of experts in 2011. These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL, risk assessment, risk-stratified treatment ...
Joseph C, Alvarnas   +26 more
openaire   +2 more sources

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia [PDF]

open access: yes, 2022
Patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a favorable prognosis. However, current treatment protocols are based on intensive cytotoxic chemotherapy and therapy options are limited when patients relapse. Hence, there is an
Gina Münch   +46 more
core   +1 more source

Adult Acute Lymphoblastic Leukemia [PDF]

open access: yesMayo Clinic Proceedings, 2005
Much progress has been made in understanding the biology of and therapy for acute lymphoblastic leukemia (ALL). This progress has translated into the recognition of several subgroups of ALL and the institution of risk-adapted therapies. New therapies are emerging based on the definition of specific cytogenetic-molecular abnormalities.
Shilpa, Paul   +2 more
openaire   +3 more sources

In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice. [PDF]

open access: yes, 2012
Xenograft mouse models represent helpful tools for preclinical studies on human tumors. For modeling the complexity of the human disease, primary tumor cells are by far superior to established cell lines.
zur Stadt, Udo   +51 more
core   +2 more sources

Clinical and molecular characterization of early T-cell precursor leukemia : a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations [PDF]

open access: yes, 2012
A subgroup of pediatric acute T-lymphoblastic leukemia (T-ALL) was characterized by a gene expression profile comparable to that of early T-cell precursors (ETPs) with a highly unfavorable outcome.
Hoelzer, Dieter   +12 more
core   +1 more source

FLT3 mutations in Early T-Cell Precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors [PDF]

open access: yes, 2013
Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) has been identified as high-risk subgroup of acute T-lymphoblastic leukemia (T-ALL) with a high rate of FLT3-mutations in adults.
Hartmut Döhner (276603)   +87 more
core   +2 more sources

Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia [PDF]

open access: yes, 2015
Although children with acute lymphoblastic leukemia (ALL) generally have a good outcome, some patients do relapse and survival following relapse is poor.
Mitchell, Chris D   +41 more
core   +1 more source

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993 [PDF]

open access: yes, 2005
The international acute lymphoblastic leukemia (ALL) study was designed to prospectively define the optimal therapy for adults 60 years of age or younger with newly diagnosed ALL.
Burnett, Alan Kenneth   +53 more
core   +1 more source

A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug l-asparaginase [PDF]

open access: yes, 2009
l-Asparaginase is a key therapeutic agent for treatment of childhood acute lymphoblastic leukemia (ALL). There is wide individual variation in pharmacokinetics, and little is known about its metabolism.
Vaskar Saha   +57 more
core   +1 more source

Home - About - Disclaimer - Privacy